Alison Marguerite Ivey

CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition

Priya Gopalan, Andres Gordillo Villegas, Chunxia Cao et al. · Oncotarget · 2018 · 49 citations · Full text

Medicine, Cancer Biology, Oncology +14

A phase II clinical trial of the CDK 4/6 inhibitor palbociclib (PD 0332991) in previously treated, advanced non-small cell lung cancer (NSCLC) patients with inactivated <i>CDKN2A</i>.

Priya Gopalan, Mary Pinder, Alberto Chiappori et al. · Journal of Clinical Oncology · 2014 · 48 citations

Medicine, Oncology, Pharmacology +17

Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma

Thomas J. George, Azka Ali, Yu Wang et al. · The Oncologist · 2021 · 15 citations · Full text

Medicine, Oncology, Pharmacology +17

Response to sunitinib in combination with proton beam radiation in a patient with chondrosarcoma: a case report

Jennifer Dallas, Iman Imanirad, Rajiv Rajani et al. · Journal of Medical Case Reports · 2012 · 12 citations · Full text

Medicine, Oncology, Radiation Oncology +15